Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
Abstract
Background The combination of doravirine and islatravir (DOR/ISL) is a novel two-drug regimen for HIV-1. Early development faced challenges due to dose-dependent immunological signals. We aimed to synthesize the evidence on the efficacy and safety of DOR/ISL across all treatment-experience categories, specifically evaluating the impact of islatravir dosage (0.25 mg vs 0.75 mg) on clinical and immunological outcomes.Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) following PRISMA guidelines. We searched PubMed, Embase, Cochrane Library, and Google Scholar from inception through April 2026. Primary outcomes were virological suppression (
Fields of Study & Subjects
HIV/AIDS drug development and treatment
HIV Research and Treatment
HIV-related health complications and treatments
Publication details
- Journal / source
- HIV Research & Clinical Practice
- Publisher
- Informa UK Limited
- Volume
- 27
- Issue
- 1
- Pages
- 2698230–2698230
- Publication date
- 4 July 2026
- Language
- EN